Información:
Error:
ID
34599
Descripción
Evaluation of Dapagliflozin Taken Twice-daily; ODM derived from: https://clinicaltrials.gov/show/NCT01217892
Link
https://clinicaltrials.gov/show/NCT01217892
Palabras clave
Versiones (1)
- 19/1/19 19/1/19 -
Titular de derechos de autor
see on clinicaltrials.gov
Subido en
19 de enero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Type 2 Diabetes NCT01217892
Eligibility Type 2 Diabetes NCT01217892
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes NCT01217892
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
ID.1
Item
provision of informed consent prior to any study specific procedures
boolean
ID.2
Item
diagnosis of t2dm
boolean
ID.3
Item
current antihyperglycaemic treatment with metformin immediate release formulation monotherapy >/= 1500 mg/day at a stable dose for at least 10 weeks prior to enrolment. other treatment with oads within the 10 weeks prior to enrolment is not permitted.
boolean
ID.4
Item
hba1c ≥ 6.7% and ≤10.5%, based on central laboratory values from screening visit, and enrolment visit 1.
boolean
ID.5
Item
diagnosis of type 1 diabetes mellitus, known diagnosis of maturity onset diabetes of the young (mody) or secondary causes of diabetes mellitus
boolean
ID.6
Item
history of diabetic ketoacidosis
boolean
ID.7
Item
symptoms of poorly controlled diabetes including, but not limited to, marked polyuria, polydipsia, and/or greater than 10% weight loss during the 3 months prior to enrolment
boolean
ID.8
Item
fpg >270 mg/dl (>15.0 mmol/l)
boolean
ID.9
Item
bmi >45 kg/m2
boolean